Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp Holdings's revenue per share for the
three
months ended in Jun. 2026 was $45.50.
Labcorp Holdings's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $173.01.
During the past 12 months, the average Revenue Per Share Growth Rate of Labcorp Holdings was 8.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 8.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 3.60% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 6.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Labcorp Holdings's Revenue per Share or its related term are showing as below:
LTS:0JSY'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.4 Med: 10.2 Max: 24.4
Current: 8.7
During the past 13 years, Labcorp Holdings's highest 3-Year average Revenue Per Share Growth Rate was 24.40% per year. The lowest was -21.40% per year. And the median was 10.20% per year.
LTS:0JSY's 3-Year Revenue Growth Rate is ranked better than 67.71% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.7
vs LTS:0JSY: 8.70
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Labcorp Holdings Revenue per Share Related Terms
Labcorp Holdings Revenue per Share Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JSY vs DGX, MTD, GH: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Labcorp Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Labcorp Holdings's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $173.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LTS:0JSY) has a Revenue per Share of $173.01 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Labcorp Holdings and its competitors. According to the industry distribution chart, Labcorp Holdings ranks #62 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 32.3%.
Is Labcorp Holdings' Revenue per Share too high?
Labcorp Holdings' current Revenue per Share is $173.01. The Medical Diagnostics & Research industry median Revenue per Share is 1.70. Labcorp Holdings' value of $173.01 is 10077.1% above this industry median. Based on the distribution chart, Labcorp Holdings ranks #62 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Revenue per Share compare to DGX and MTD?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #62 out of 192 companies for Revenue per Share. This puts Labcorp Holdings in the upper half of its industry. The industry median Revenue per Share is 1.70. Labcorp Holdings' value of $173.01 is 10077.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.70, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current Revenue per Share of $173.01 is 10077.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current Revenue per Share is $173.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Modestly Overvalued. The stock's GF Value™ is $277.11, compared to a current price of $334.38 — trading 20.7% above its estimated fair value. The current Revenue per Share is $173.01 and 10077.1% above the Medical Diagnostics & Research industry median of 1.70. Labcorp Holdings' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current Revenue per Share is $173.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $334.38 is trading 20.7% above its estimated GF Value™ of $277.11.
GuruFocus considers Labcorp Holdings to be Modestly Overvalued.
Key valuation signals for LTS:0JSY:
Revenue per Share: $173.01
GF Value™: $277.11 vs. price of $334.38 (20.7% above fair value)
Industry Position: 10077.1% above the Medical Diagnostics & Research median (#62 of 192)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
76GF Score
Get the complete analysis for LTS:0JSY
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
